A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

Also called NCT06937203

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06937203
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, New Zealand (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06937203. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-09 (actual); primary completion 2027-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Condition
Obesity
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
ARO-ALK7
Intervention (Drug)
Placebo
Lead sponsor
Arrowhead Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06937203
Content hash
1a2b747c415262f04bc7d91d757068fd89e0c2b19f239804e0959aff2436b080